11th European Biosimilars Congress
Event Apr 26 - Apr 27, 2018
Location: Rome, Italy
Theme: The Developmental Strategies and Uptake of Biosimilars through a Decade in Europe
Conference series takes pleasure in inviting the scientific community across the globe to attend the 11th European Biosimilars Congress during April 26-27, 2018 at Rome, Italy with a motto to Explore Innovations in Biosimilars & Biologics. This European Biosimilars Congress 2018 will bring together Professors, scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials, CROs and students from around the world. The passage of biosimilars through a decade at Europe finds much requirement for discussion also focussing the latest developments in the field of biologics and biosimilars.
Kamali Chance, Quintiles Inc.,, USA; Ruideger Janwosky, Cinfa Biotech GmbH, Germany; Christoph Volpers, Michalski Hüttermann & Partner Germany; Arthur G Cook, ZS Associates USA; Stanley Seung Suh Hong, Celltrion Healthcare Co. Ltd. South Korea; Fiona M Greer, SGS Life Sciences, Switzerland; András Guttman, University of Pannonia,Hungary SCIEX, USA; Ulrike Konrad, Protagen Protein Services , Germany; Tim Demuth, Sandoz Pharmaceuticals GmbH, Germany; Rosa Helena Bustos, University of La Sabana, Colombia; Tsachi Shaked, E3D (Elcam Drug Delivery Devices), Israel; Efraín Esteban, University of La Sabana, Colombia; Ulrich Storz Michalski Hüttermann & Partner, Germany; Andreu Soldevila, CEO LeanBioPro, Spain; Laszlo Endrenyi, University of Toronto, Canada; Raymond A Huml, Quintiles, Inc., USA; Patrick Lucy Pfenex Inc., USA;
The important tracks that are part of Euro Biosimilars 2018 includes:
Current Challenges in Developing Biosimilars, Emerging Biosimilars in Therapeutics, Analytical Strategies for Biosimilars, Regulatory Approach of Biosimilars, Biosimilar Companies and Market Analysis, Innovative Approach for Biosimilars, Clinical Development of Biosimilars, Consequences of Brexit on Biosimilars, Intellectual Property Rights, Globalization of Biosimilars, Bioequivalence Assessment, Biosimilars Research Pipeline, BCS and IVIVC Based Biowaivers, Biosimilar Market and Cost Analysis, Challenges in Biosimilars Pharmacovigilance, Legal Issues and BPCI Act, Entrepreneurs Investment Meet
Euro Biosimilars 2018 is comprised of 17 tracks and 90 sessions designed to offer comprehensive sessions that address current issue. For more scientific sessions and abstract submission, please visit:
The Abstracts that are accepted for presentations are published in the proceedings of the Journals like Journal of Bioanalysis & Biomedicine, Journal of Bioequivalence & Bioavailability : Open Access.
Grab the opportunity to participate by registering through flowing link:
For further details, please contact:
Badoni Victor | Program Director
Direct: (702) 508-5200 Ext: 8028
Customer Service: +1 (800) 216 6499